Yazar "Canoruc N." seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Blood glucose fructosamin and HbAlc levels in cases with diabetes mellitus(1992) Yenice N.; Kaplan A.; Batun S.; Canoruc N.In this research serum glucose, fructosomin and erytroid HbAlc levels were investigated in 50 patiens with diabetes mellitus (Type I and II) and result were compared with the normal control values. (25 normal people) In the control group the levels of serum glucose, fructosamin and erytroid HmAlc were obtained as % 94.52 ± 7.7 mg; 2.29 ± 0.299 mmol/L; % 7.02 ± 0.742 respectively. In cases with Diabetes mellitus the levels of serum glycose, fructosamin and erytroid HbAlc were obtained as % 270.83 ± 98.49 mg, 4.02 ± 0.942 mmol/L, % 13.09 ± 2.387 respectively. The levels of serum glucose, fructosamine and erytroid HbAlc were increased significantly in patients with diabetes mellitus as compared with control group (p < 0.001). The serial determinations of serum fructozamin and erytroid HbAlc levels are of value in cases with diabetes mellitus in the diagnosis, treatment and in estimation of complications of diabetes mellitus which will appear in future.Öğe The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients: A prospective, randomised, double-blind, placebo-controlled study(SMW supporting association, 2003) Dursun M.; Caliskan M.; Canoruc F.; Aluclu U.; Canoruc N.; Tuzcu A.; Yilmaz S.Hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with fulminant hepatic failure and chronic liver disease. Its pathogenesis is unclear. One of the factors implicated is enhanced GABA-ergic tone, which is probably related to increased concentrations of cerebral benzodiazepine (BNZ). In the present study, we tested flumazenil, a cerebral BNZ antagonist, in cirrhosis patients with hepatic encephalopathy. Methods: Out of 47 patients, 7 were excluded prior to randomization for various reasons. Twenty patients were included in the flumazenil group and 20 in the placebo group in a prospective, randomized, double-blind, placebo-controlled study. Patients were given flumazenil (1 mg/h, continuous IV infusion) or an equal volume of saline solution for 5 hours. Before and after treatment, portosystemic encephalopathy (PSE) stage and number connection test (NCT) scores were checked every half hour for 5 hours. EEG was recorded 15 minutes before and 1 hour after treatment. Results: While significant improvements were determined in PSE stage and NCT score in the flumazenil group, there were no such improvements in the placebo group. There was no statistically significant difference between pre- and post-treatment EEGs in either group. Conclusion: It was concluded that continuous IV infusion of flumazenil had beneficial and safe effects in the treatment of hepatic encephalopathy patients.Öğe Preventive action of omeprazole, famotidine or nitrendipine against stress ulcer formation in rats(1994) Canoruc N.; Ulak G.; Guzel C.; Kaya H.; Cicek R.The effects of H+/K+-ATP ase inhibitor, omeprazole, the H2-receptor antagonist, famotodine, and the calcium channel antagonist, nitrendipine, on gastric ulcers, gastric mucosal barrier and gastrin release were investigated in cold-restraint stress-induced rats. Omeprazole (30 mg/kg i.g.) famotidine (1 mg/kg, i.g.) and nitrendipine (16 mg/kg, i.p.) significantly prevented gastric ulceration. Nitrendipine reduced the mucus secretion and exhibited no important change in phospholipid content; thus, it failed to restore the damage in the gastric mucosal barrier due to cold-restraint stress. Omeprazole increased mucus secretion and phospholipid content of gastric mucosal barrier whereas famotidine tended to cause an increase in mucus and phospholipid levels; however, this difference did not attain statistical significance. Serum gastrin levels revealed lower values in the nitrendipine group as compared with controls; whereas it increased in omeprazole and famotidine groups, but more significantly in the omeprazole treated group.
